Laboratoriotoiminnan yksikkö

Julkaisut 2006
Publications 2006

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Eskelinen SI et al. Actual practice vs guidelines in laboratory monitoring of older patients with primary hypothyroidism in primary care.
2 Haapamäki MM et al. Value of blood tests including serum group IIA phospholipase A2 and bactericidal/permeability-increasing protein in Crohn's disease.
3 Hellstén S. Verensiirto-opas 2006.
4 Isoniemi H et al. Hippocampal volume, brain atrophy, and APOE genotype after traumatic brain injury.
5 Isoniemi H et al. Outcome of traumatic brain injury after three decades - relationship to ApoE genotype.
6 Juvonen V, Penttinen M. Epätyypilliset periytymistavat.
7 Kaitosaari T et al. Low-density lipoprotein (LDL) particle size in healthy prepubertal children: The STRIP study.
8 Kallio K et al. Impact of repeated lifestyle counselling in an atherosclerosis prevention trial on parental smoking and children's exposure to tobacco smoke.
9 Kalliokoski RJ et al. Structural and functional changes in peripheral vasculature of Fabry patients.
10 Kankuri M et al. The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma.
11 Karvonen J et al. Stone or stricture as a cause of extrahepatic cholestasis - do liver function tests predict the diagnosis?
12 Koivusalo R et al. Activation of p53 in cervical cancer cells by human papillomavirus E6 RNA interference is transient, but can be sustained by inhibiting endogenous nuclear export-dependent p53 antagonists.
13 Kotilainen P et al. Aetiological diagnosis of infective endocarditis by direct amplification of rRNA genes from surgically removed valve tissue. An 11-year experience in a Finnish teaching hospital.
14 Kupila L et al. Brain abscess caused by Mycoplasma hominis: A clinically recognizable entity?
15 Lautamäki R et al. The effect of PPARgamma-agonism on LDL subclass profile in patients with type 2 diabetes and coronary artery disease.
16 Meurman O et al. Evaluation of Vitek 2 for identification of yeasts in the clinical laboratory.
17 Meurman O, Nissinen A. Bakteerilääkeherkkyyskiekkojen säilyminen ja säilyttäminen.
18 Palo R et al. Development of permanent national register of blood component use utilizing electronic hospital information systems.
19 Rantakokko-Jalava K et al. Comparison of workflow and accuracy of identification and antimicrobial susceptibility testing of clinical isolates of Enterobacteriaceae, Pseudomonas aeruginosa and enterococci by Vitek 2 and routine methods.
20 Ruohola A et al. Microbiology of acute otitis media in children with tympanostomy tubes: Prevalences of bacteria and viruses.
21 Ruotsalainen E et al. Levofloxacin does not decrease mortality in staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients.

Julkaisutietokanta 23.10.2007 Publications Data Base 23.10.2007